TORONTO, Jan. 6, 2025 /PRNewswire/ – Myant Corp., a leader in chronic disease prevention through precision medicine, announced the acquisition of mmHg Inc., a digital health company focused on remote blood pressure monitoring Specializing in cardiovascular risk reduction and chronic disease management. This acquisition expands Myant’s geographic footprint and market coverage into the United States, where mmHg has a significant customer base, including a partnership with one of the largest manufacturers of high-precision, reliable medical devices and healthcare products, A&D Medical.
This acquisition is part of a broader “prevention through precision” strategy to drive a new era of personalized, AI-powered remote care.
mmHg’s platform focuses on providing efficient, guideline-compliant care for the management of cardiovascular health, particularly in remote areas. The innovative software gives healthcare providers the ability to remotely track and analyze blood pressure and a full range of important cardiovascular indicators. By aligning patient data with clinical best practices, mmHg improves the precision of decision-making, promoting timely and precise interventions. Renowned institutions across North America, such as Beth Israel Deaconess (Harvard Medical), Johns Hopkins, Columbia University, NYU, Tulane University and the University of British Columbia, rely on the platform to improve both patient care and clinical research.
By combining mmHg’s advanced remote monitoring capabilities with Myant’s advanced materials and textile computing technology, healthcare providers gain access to continuous, real-time patient data that enables earlier detection of health risks, personalized treatment plans and better management of chronic diseases. The result is early disease detection, which improves health status, reduces hospitalizations and increases quality of life.
“Our company is committed to making healthy aging a reality for millions of people. We want to declare war on chronic diseases and redefine what it means to grow older. This acquisition enhances our ability to provide comprehensive cardiovascular monitoring and risk management solutions. “In doing so, we are strengthening our role in transforming digital health and enabling this large, aging population to live younger and longer,” said Tony Chahine, CEO of Myant.
“The combination of Myant’s innovative textile technology and mmHg’s clinically sound software architecture will undoubtedly create the next generation of personalized care delivery, where patients will be able to transmit clinically relevant, continuous vital data to a platform that delivers the data in an efficient and clinically relevant way for care teams,” said Peter Wood, co-founder and chief operating officer of mmHg Inc.
This strategic acquisition aligns with Myant’s ongoing efforts to leverage AI and advanced materials to improve patient outcomes and extend human life, and adds new capabilities to Myant’s fully vertically integrated solutions
Information about Myant:
Myant’s goal is to enable and improve quality of life for everyone. We leverage advances in AI, medicine and advanced materials to promote health, safety, connection and confidence at every stage of life.
Myant is leading a development where AI guardians can enhance human capabilities through textile interfaces, a connected, protective second skin. Made from groundbreaking modern materials, this second skin blends naturally into our everyday lives and sets new standards for seamless interaction with the digital world.
From early to late life, AI guardians have the potential to improve well-being, ensure safety, redefine the way we connect with society, and ensure universal access to the best possible care at every point in time make possible.
In 2024, Myant expanded into the EU with significant growth and brought on world-renowned AI scientist Dr. Xin Gao on board as Chief AI Officer.
About mmHg Inc:
mmHg Inc. is a digital health company providing remote blood pressure monitoring and cardiovascular risk management solutions. Your products from Dr. Co-developed by Raj Padwal (former CEO and principal founder of mmHg), a leader in cardiovascular risk reduction, blood pressure monitoring and technology-enabled care, are designed to improve clinical care and are used by healthcare providers and researchers across North America.
Myant at the Consumer Electronic Show (CES) 2025
From January 7-10, 2025, Myant will be at booth 53618 at the Venetian Expo & Convention Center, 201 Sands Ave. in Las Vegas, NV 89169, USA.
For further information please contact:
Charles Andreo
Logo – https://mma.prnewswire.com/media/2591480/Myant_and_mmHg.jpg
Logo – https://mma.prnewswire.com/media/2569573/5100779/Myant_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/myant-erwirbt-mmhg-inc-zur-verbesserung-der-prazisionsmedizin-fur-die-kardiovaskulare-versorgung-302343469.html